Jamey Millar
Jamey Millar is the newly appointed head of operations for Novo Nordisk in the United States, recently in the news for announcing significant price reductions on the company's leading obesity treatment, Wegovy, and diabetes medication, Ozempic, in an effort to improve access for millions affected by obesity and Type 2 diabetes.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United States | 1 | 8.00 | 0.05% | +0% | 331,002,651 | 173,028 | $21,000,000 | 10,978$ |
| Totals | 1 | 331,002,651 | 173,028 | $21,000,000 | 10,978$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Jamey Millar stressed the overall health benefits of Wegovy, including lower risk of cardiovascular problems.
8
France:
Jamey Millar is the new head of operations for Novo Nordisk in the United States.
7